Home › NCT06745466
Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women
RecruitingPhase 4Healthy volunteers welcome
Who can join
Ages 40 to 55 · Women · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Female * Age 40-55 * Premenopausal Exclusion Criteria: * Pregnancy (including a positive urine pregnancy test), planning to become pregnant, or breast-feeding * Peri- or post-menopausal * Unstable or diagnosed chronic clinical disease, including cardiovascular, metabolic, renal, hepatic, autonomic, autoimmune, or dermatological disease * Current or lifetime major psychiatric illness (e.g., major depressive disorder, bipolar disorder, schizophrenia, eating disorders) * History of hysterectomy (complete or partial), polycystic ovary syndrome, endometrial hyperplasia, irregular menstrual cycles, or endometrial ablation * Suspected potential presence of obstructive sleep apnea (STOP-Bang score \>3) or insomnia (Insomnia Severity Index score \>15) * Current or recent (within 8 wks) use of medications that could conceivably alter cardiovascular function or sleep health * Changes or alterations in medication status (starting a new, additional, or different medication or changing the dose of a current medication) * Body mass index \>35 kg/m2 * Tobacco or nicotine use, including vaping and electronic cigarettes * Working night-time or rotating shift work within the previous 3 months * Trans-meridian travel during study enrollment (inclusive of the entire duration of enrollment and the period between testing cycles) * Known allergies to pharmacological agents/drugs * Current use of long-acting reversible contraception (LARC; e.g., IUDs, birth control implants) * Known latex allergy
About the study
The purpose of this study is to identify the impact of estradiol (E2) on the associations between (a) responsivity to daily stress or (b) sleep variability with vascular function in midlife premenopausal women.
What is being tested
- ganirelix acetate (drug)
Sponsor: University of Delaware · Participants: 30 · Started: Nov 15, 2024
Contact the study team
- Jody Greaney, PhD · Phone: 302-831-2193
Official record on ClinicalTrials.gov — NCT06745466
Locations in the U.S.
| Delaware | University of Delaware, Newark |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.